Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Stryker Corporation reported that VP and Chief HR Officer M. Kathryn Fink received an employee stock option award. On 02/04/2026 she was granted options to purchase 5,654 shares of Stryker common stock at an exercise price of $360.82 per share.
These options vest in stages, with 20% becoming exercisable on each of the first five anniversaries of the grant date, and they expire on 02/03/2036. The grant was made under the Stryker Corporation 2011 Long-Term Incentive Plan and is held directly by the executive.
Stryker Corporation granted a new stock option award to its VP and Chief Legal Officer, Robert S. Fletcher. On 02/04/2026, he received an employee stock option for 8,980 shares of Stryker common stock at an exercise price of $360.82 per share.
The option was granted under the Stryker Corporation 2011 Long-Term Incentive Plan and becomes exercisable as to 20% on each of the first five anniversaries of the grant date, creating a five-year vesting schedule tied to continued service.
Stryker Corporation granted stock options to senior executive Dylan Bram Crotty, its Group President. On 02/04/2026, he received an employee stock option for 9,978 shares of common stock at an exercise price of $360.82 per share, held directly.
The option was granted under the Stryker Corporation 2011 Long-Term Incentive Plan and becomes exercisable as to 20% of the shares on each of the first five anniversaries of the grant date, with an expiration date of 02/03/2036.
Stryker Corporation reported that Group President Viju Menon received an employee stock option grant on February 4, 2026. The award covers 10,310 options to buy Stryker common stock at an exercise price of $360.82 per share.
These options were granted under the Stryker Corporation 2011 Long-Term Incentive Plan and become exercisable in stages, with 20% vesting on each of the first five anniversaries of the grant date. Following this grant, Menon beneficially owns 10,310 derivative securities directly in the form of these options.
Stryker Corporation reported that its VP and Chief Financial Officer, Preston Wendell Wells, received an employee stock option grant. On February 4, 2026, he was granted 11,974 stock options with an exercise price of $360.82 per share under the Stryker Corporation 2011 Long-Term Incentive Plan.
The options vest in stages, becoming exercisable as to 20% on each of the first five anniversaries of the grant date, and are scheduled to expire on February 3, 2036. Following this grant, he beneficially owns 11,974 derivative securities directly.
Stryker Corporation granted Group President James Andrew Pierce new equity awards on February 4, 2026. He received 2,771 Restricted Stock Units (RSUs) that vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029, each RSU representing one share of common stock.
Pierce was also granted an employee stock option for 15,300 shares of Stryker common stock at an exercise price of $360.82 per share. The option becomes exercisable as to 20% of the shares on each of the first five anniversaries of the grant date and expires on February 3, 2036. After these awards, he holds 73,334 shares directly, plus additional indirect holdings through his sons and a 401(k) account.
Stryker Corporation reported that President and COO Spencer S. Stiles received an employee stock option grant on February 4, 2026. The grant covers 19,956 stock options with an exercise price of $360.82 per share, giving him the right to buy Stryker common stock at that price.
These options were issued under the Stryker Corporation 2011 Long-Term Incentive Plan and vest over time, becoming exercisable in 20% increments on each of the first five anniversaries of the grant date. The options expire on February 3, 2036, and are held directly by Stiles.
Stryker Corporation Chair and CEO Kevin Lobo reported several equity transactions and a new option grant. On February 6, 2026, he exercised 206,955 employee stock options at $96.64 per share, acquiring the same number of Stryker common shares.
That same day, 132,410 shares of common stock were disposed of at $362.42 per share in a transaction coded “F,” typically used for tax withholding, leaving him with 196,940 directly held shares plus 721 shares held indirectly via a 401(k). On February 4, 2026, he also received a new grant of 58,206 stock options with an exercise price of $360.82 per share, expiring on February 3, 2036.
Stryker Corporation’s President and COO, Spencer S. Stiles, reported option exercises and share dispositions. On 02/03/2026, he exercised 13,840 employee stock options at $96.64 per share, receiving the same number of common shares. That day, 7,692 common shares were disposed of at $368.14 per share. After these transactions, he held 68,982 common shares directly and 1,670 shares indirectly through a 401(k).
Stryker Corporation Group President James Andrew Pierce reported several share transactions on 02/02/2026. He exercised an employee stock option for 13,840 shares of Common Stock at $96.64 per share and acquired the underlying shares. To cover associated obligations, 8,432 shares of Common Stock were disposed of at $369.56 per share. He also sold 475 shares of Common Stock in open-market transactions at a weighted average price of $368.873 per share, with individual trades ranging from $368.7534 to $368.92. After these transactions, he directly owned 70,563 shares of Common Stock and held indirect interests in 712 shares and 713 shares through his sons and 1,595 shares through a 401(k) plan. The option grant from 02/10/2016 was fully exercised, leaving 0 derivative securities outstanding from that grant.